Innovative three-step microwave-promoted synthesis of N-propargyltetrahydroquinoline and 1,2,3-triazole derivatives as a potential factor Xa (FXA) inhibitors: Drug design, synthesis, and biological evaluation.

Vista sencilla de ítem
dc.contributor.authorSantana-Romo, Fabián
dc.contributor.authorLagos, Carlos F.
dc.contributor.authorDuarte, Yorley
dc.contributor.authorCastillo, Francisco
dc.contributor.authorMoglie, Yanina
dc.contributor.authorMaestro, Miguel A.
dc.contributor.authorCharbe, Nitin
dc.contributor.authorZacconi, Flavia C.
dc.date.accessioned2023-04-04T21:25:01Z
dc.date.available2023-04-04T21:25:01Z
dc.date.issued2020-01
dc.descriptionIndexación: Scopuses
dc.description.abstractThe coagulation cascade is the process of the conversion of soluble fibrinogen to insoluble fibrin that terminates in production of a clot. Factor Xa (FXa) is a serine protease involved in the blood coagulation cascade. Moreover, FXa plays a vital role in the enzymatic sequence which ends with the thrombus production. Thrombosis is a common causal pathology for three widespread cardiovascular syndromes: acute coronary syndrome (ACS), venous thromboembolism (VTE), and strokes. In this research a series of N-propargyltetrahydroquinoline and 1,2,3-triazole derivatives as a potential factor Xa (FXa) inhibitor were designed, synthesized, and evaluated for their FXa inhibitor activity, cytotoxicity activity and coagulation parameters. Rational design for the desired novel molecules was performed through protein-ligand complexes selection and ligand clustering. The microwave-assisted synthetic strategy of selected compounds was carried out by using Ullmann-Goldberg, N-propargylation, Mannich addition, Friedel-Crafts, and 1,3-dipolar cycloaddition type reactions under microwave irradiation. The microwave methodology proved to be an efficient way to obtain all novel compounds in high yields (73–93%). Furthermore, a thermochemical analysis, optimization and reactivity indexes such as electronic chemical potential (μ), chemical hardness (η), and electrophilicity (ω) were performed to understand the relationship between the structure and the energetic behavior of all the series. Then, in vitro analysis showed that compounds 27, 29–31, and 34 exhibited inhibitory activity against FXa and the corresponding half maximal inhibitory concentration (IC50) values were calculated. Next, a cell viability assay in HEK293 and HepG2 cell lines, and coagulation parameters (anti FXa, Prothrombin time (PT), activated Partial Thromboplastin Time (aPTT)) of the most active novel molecules were performed to determine the corresponding cytotoxicity and possible action on clotting pathways. The obtained results suggest that compounds 27 and 29 inhibited FXa targeting through coagulation factors in the intrinsic and extrinsic pathways. However, compound 34 may target coagulation FXa mainly by the extrinsic and common pathway. Interestingly, the most active compounds in relation to the inhibition activity against FXa and coagulation parameters did not show toxicity at the performed coagulation assay concentrations. Finally, docking studies confirmed the preferential binding mode of N-propargyltetrahydroquinoline and 1,2,3-triazole derivatives inside the active site of FXa. © 2020 by the authors.es
dc.description.urihttps://www.mdpi.com/1420-3049/25/3/491
dc.identifier.citationMolecules Volume 25, Issue 323 January 2020 Article number 491es
dc.identifier.doi10.3390/molecules25030491
dc.identifier.issn1420-3049
dc.identifier.urihttps://repositorio.unab.cl/xmlui/handle/ria/48195
dc.language.isoenes
dc.publisherMDPIes
dc.rights.licenseAtribución 4.0 Internacional (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/deed.es
dc.subject1,2,3-triazolees
dc.subjectCell viability assayes
dc.subjectCoagulation parameterses
dc.subjectFactor Xa inhibitorses
dc.subjectMicrowave-assisted synthesises
dc.subjectN-propargyltetrahydroquinolinees
dc.titleInnovative three-step microwave-promoted synthesis of N-propargyltetrahydroquinoline and 1,2,3-triazole derivatives as a potential factor Xa (FXA) inhibitors: Drug design, synthesis, and biological evaluation.es
dc.typeArtículoes
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Santana_F_Innovate_Three_Step_Microware_Promoted_2020_Article.pdf
Tamaño:
8.41 MB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLES
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
Fac.CV - Artículos de Revista